Community-acquired necrotizing pneumonia due to methicillin-sensitive Staphylococcus aureus secreting Panton-Valentine leukocidin: a review of case reports
© Kreienbuehl et al; licensee Springer. 2011
Received: 20 September 2011
Accepted: 22 December 2011
Published: 22 December 2011
Community-acquired necrotizing pneumonia caused by Panton-Valentine leukocidin (PVL)-secreting Staphylococcus aureus is a highly lethal infection that mainly affects healthy children and young adults. Both methicillin-sensitive S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) may carry the PVL-phage, but the majority of publications relate to community-associated methicillin-resistant S. aureus (CA-MRSA) or mixed patient groups. This study focuses on necrotizing pneumonia due to methicillin-sensitive S. aureus strains, with the purpose to determine factors associated with outcome.
We report a patient with PVL secreting MSSA necrotizing pneumonia and performed a systematic review of similar case in the literature. We analyzed factors associated with outcome.
A total of 32 patient descriptions were retained for analysis. Septic shock (p = 0.007), influenza-like prodrome (p = 0.02), and the absence of a previous skin and soft-tissue infection (p = 0.024) were associated with fatal outcome. In multivariate analysis, influenza-like prodrome (odds ratio (OR), 7.44; 95% confidence interval (CI), 1.24-44.76; p = 0.028) and absence of previous skin and soft-tissue infection (OR, 0.09; 95% CI, 0.01-0.86; p = 0.036) remained significant predictors of death.
Influenza-like prodrome may be predictive of adverse outcome in PVL-secreting MSSA necrotizing pneumonia. In contrast, previous skin and soft-tissue infection may be associated with improved prognosis.
Staphylococcus aureus is estimated to cause 1-10% of community acquired pneumonias (CAP) and 20-50% of nosocomial pneumonias . It is an important factor of influenza-related morbidity and mortality and approximately half of the patients with S. aureus pneumonia have underlying comorbidities and risk factors [2, 3]. In 1999, Lina et al. found an association between necrotizing pneumonia and Panton-Valentine leukocidin (PVL)-secreting S. aureus . In 2002, Gillet et al. defined the clinical features of PVL-associated necrotizing pneumonia, followed in 2007 by the description of risk factors associated with mortality [5, 6]. PVL is thought to be a key factor in the pathogenesis of necrotizing pneumonia. It forms pores in the cell and mitochondrial membrane of neutrophils and macrophages and thus provokes cell lysis and apoptosis with subsequent liberation of inflammatory mediators [4, 7]. Some authors contest the pathogenic potential of PVL and suggest the presence of PVL-genes to be a marker of other virulence determinants [8, 9].
The global distribution of PVL-carrying S. aureus varies geographically. In North America, the most dominant clone is ST8-USA300, which is responsible for the majority of community-associated methicillin-resistant S. aureus MRSA (CA-MRSA)-related infections [10, 11]. European isolates are more commonly methicillin-sensitive S. aureus (MSSA) [4, 6]. Overall, the prevalence of PVL-carrying S. aureus seems to be increasing. A U.S. wide study examining the proportion of CA-MRSA among S. aureus CAP during the 2006-2007 influenza seasons found a prevalence of 79%, in contrast to 12% between 1986 and 2005 . The Health Protection Agency Staphylococcus Reference Unit (HPA-SRU) in England recorded a steady increase of PVL-positive S. aureus between 2005 and 2009, with a majority of strains being methicillin-sensitive (61.5% versus 38.5% in 2010) . Molecular profiles of methicillin-sensitive and methicillin-resistant PVL-carrying S. aureus reveal close genetic similarity and the former are thought to constitute a reservoir for the latter .
Current knowledge about clinical features and mortality of PVL-positive S. aureus necrotizing pneumonia is based on series and case reports. The typical clinical picture is a previously healthy child or young adult with an influenza-like prodrome, who rapidly develops septic shock and respiratory failure, in the context of multilobar consolidation, pleural effusion, and airway hemorrhage . Influenza-like prodrome, leuko- and thrombocytopenia, airway hemorrhage, and pleural effusion are considered predictive of fatal outcome . Published mortality rates vary between 40% and 60% [3, 6, 14, 15]. One study compared outcome between MSSA and MRSA strains, without finding a significant difference .
We report a patient with PVL-secreting MSSA-necrotizing pneumonia, who had a classical clinical presentation and was successfully treated with antitoxin antibiotics and intravenous immunoglobulin. He was included in a review and analysis of clinical characteristics of reported patients with a PLV-positive methicillin-sensitive S. aureus necrotizing pneumonia, with the goal to confirm outcome factors.
We searched for case reports and case series about PLV-positive MSSA-community-acquired pneumonias published before April 2010, using PubMed, with the search terms "community-acquired pneumonia," "necrotizing pneumonia," and "Panton-Valentin leukocidin." The reference sections of case reports, case series, and relevant research and review articles were scanned for missed case reports and case series. Case series, which lacked individual clinical patient descriptions, were excluded. Only articles in English, French, and German were analyzed. The patient treated in our own institution was included in the analysis. The extracted clinical, microbiological, and outcome data were converted into variables and analyzed accordingly. For continuous variables, results are summarized as mean ± SD and categorical variables are expressed in proportions. Fisher's exact test and Student's t test were used for categorical and continuous variables, respectively. Variables significantly associated with outcome in the univariate analysis were included in a multivariable model. For all tests, a two-tailed P value < 0.05 was considered to denote statistical significance. Data analysis was performed with SAS 9.2 (SAS Institute Inc.: Cary, NC, USA).
Univariate analysis of risk factors associated with mortality in patients with PVL-secreting MSSA-necrotizing CAP
(N = 13)
(N = 19)
OR (95% CI)
Age (yr), mean ± SD
25.6 ± 15.5
23.7 ± 17.2
Confirmed influenza coinfection
SSTI on admission
T° < 36° or > 38° on admission
Lower airway hemorrhageb
Positive blood cultures
First-line antibiotics targeting toxin productionc
The average age was 24.5 (interquartile range, 14-38) years, and 13 patients died (41%). With the exception of one patient who died after 20 days, the median time from admission to death was 20 hours. Univariate analysis found that influenza-like prodrome (p = 0.02), absence of skin and soft tissue infection (SSTI) on admission (p = 0.024), and septic shock (p = 0.007) were associated with death (Table 1). The multivariable model confirmed an association with fatal outcome for influenza-like prodrome (OR, 7.44; 95% CI, 1.24-44.76; p = 0.028) and absent SSTI (OR, 0.09; 95% CI, 0.01-0.86; p = 0.036). Among patients with SSTI, there was a lower rate of preceding influenza-like syndrome (p = 0.0008), septic shock (p = 0.014), mechanical ventilation (p = 0.047), and lower mortality (p = 0.024). None of the patients received an initial antibiotherapy targeting the PVL toxin production.
Community-acquired necrotizing pneumonia due to S. aureus- secreting PLV toxin is a highly lethal infection, affecting a young and healthy population group . The hallmarks are an influenza-like prodrome, leukopenia, rapid progression to septic shock, and respiratory distress, with multilobar necrosis and haemoptysis [5, 6, 14].
In this series, the mortality rate was 41%, which is lower than most of previously published rates [3, 5, 14, 15]. On multivariable analysis, influenza-like prodrome predicted fatal outcome. The true proportion of influenza infection is difficult to assess, because influenza testing is not routinely performed and rapid test sensitivity is only 50-70% . Influenza impedes phagocytic killing and damages the trachea-bronchial epithelium with subsequent impairment of secretion clearance and facilitated bacterial adhesion [42–44]. The influenza-like prodrome also may be caused by other respiratory viruses or by S. aureus itself.
We found a significant reduction of mortality for patients with skin and soft-tissue infection on admission. This result is new in the context of PVL-associated S. aureus necrotizing pneumonia, although one study mentioned a nonsignificant trend toward lower mortality for patients with a history of furuncles  and a recent retrospective study found a significant protective effect of a history of PVL-associated infections . Similar results also have been published in studies on S. aureus carriers. Approximately 20-30% of healthy persons are persistently colonized with S. aureus [44, 46]. When hospitalized, these carriers have an increased risk of developing severe S. aureus infection caused by their colonizing strain , but mortality of S. aureus bacteremia is much lower in carriers than in noncarriers . The likely explanation for this protective effect is the stimulation of an immune response, which lowers the intensity of a subsequent invasive infection . A PVL vaccine has already been successfully tested on mice models and may find a human application in the near future .
Another issue raised by this study is the high rate of inadequate initial antibiotic treatment regimens. None of the 32 published cases received an antibiotic with an antitoxin effect as part of their first-line treatment, and all but three patients received beta-lactams. The use of beta-lactams as first-line treatment is controversial, because drug levels below the minimum inhibitory concentration may increase toxin release and stimulate toxin production [37, 38, 51]. The former effect is due to release of intracellular toxin secondary to cell wall lysis. In vivo, low drug levels in target tissues are a consequence of extensive tissue necrosis, leading to poor antibiotic diffusion and a sepsis-related increase of the volume of distribution. However, the stimulatory effect on toxin release is reversed when beta-lactams are given in association with clindamycin, linezolid, or rifampicin . The high rate of inadequate initial antibiotic treatment may be explained by the low prevalence of necrotizing S. aureus pneumonia, the low specificity of initial clinical signs and symptoms, and the adherence to treatment guidelines for community-acquired pneumonias. However, even after overt clinical suspicion or microbiological confirmation of PVL-secreting S. aureus, only 36% (5/14) of second-line antibiotics were adequate. Not surprisingly, the rate of adequacy was higher among more recent case reports. Since 2007, the Infectious Diseases Society of America (IDSA) recommends adding vancomycin or linezolid in case of severe pneumonia due to CA-MRSA . In the United Kingdom, the Health Protection Agency (HPA) recommends a combination of clindamycin, linezolid, and rifampicin but explicitly dissuades from the use of beta-lactams . Based on the discussed in vitro findings for beta-lactams, a recent recommendation by Gillet et al. suggests a third-generation cephalosporin with vancomycin and clindamycin or linezolid as first-line antibiotherapy. In the case of MSSA, vancomycin can be replaced by oxacillin .
Intravenous immunoglobulin may be an important adjunct to antibiotherapy. As illustrated in the above and in other case reports, it has been used successfully on a sporadic basis [30, 36, 56]. It was studied in vitro and was shown to neutralize PVL-induced pore formation and cytopathic effect . The HPA recommends intravenous immunoglobulin at a dose of 2 g/kg to be repeated after 48 hours if there is persistence of septic shock or failure to respond .
The significance of our study results is limited by its reliance on a relatively small number of case reports. Also, many variables, such as thrombocytopenia or kidney function, were reported infrequently and thus could not be included in the statistical analysis. We suspect that only the most severe cases of CAP caused by PVL-secreting MSSA are reported and that many cases are not detected, making it difficult to describe the full spectrum of clinical illness and to form meaningful conclusions based on the case reports. To improve our knowledge of the epidemiology, diagnosis, and treatment, there is a need to establish an international database.
Necrotizing pneumonia due to PVL-secreting S. aureus mandates prompt recognition and specific treatment to prevent premature death in immunocompetent patients. Early suspicion should be triggered by the presence of influenza-like prodrome, leucopenia, rapid progression to septic shock, respiratory distress with multilobar necrosis, and hemoptysis. For PVL-secreting MSSA-necrotizing pneumonia, influenza-like prodrome may be associated with fatal outcome, whereas previous SSTI may reduce mortality. Further studies based on a larger patient number are necessary to confirm this finding.
- Howard LS, Sillis M, Pasteur MC, Kamath AV, Harrison BD: Microbiological profile of community-acquired pneumonia in adults over the last 20 years. J Infect 2005, 50: 107–113. 10.1016/j.jinf.2004.05.003PubMedView Article
- Chickering HT, Park JH Jr: Staphylococcus aureus pneumonia. JAMA 1919, 72: 617–626. 10.1001/jama.1919.02610090001001View Article
- Kallen AJ, Brunkard J, Moore Z, Budge P, Arnold KE, Fosheim G, Finelli L, Beekmann SE, Polgreen PM, Gorwitz R, Hageman J: Staphylococcus aureus community-acquired pneumonia during the 2006 to 2007 influenza season. Ann Emerg Med 2009, 53: 358–365. 10.1016/j.annemergmed.2008.04.027PubMedView Article
- Lina G, Piemont Y, Godail-Gamot F, Bes M, Peter MO, Gauduchon V, Vandenesch F, Etienne J: Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999, 29: 1128–1132. 10.1086/313461PubMedView Article
- Gillet Y, Issartel B, Vanhems P, Fournet JC, Lina G, Bes M, Vandenesch F, Piémont Y, Brousse N, Floret D, Etienne J: Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002, 359: 753–759. 10.1016/S0140-6736(02)07877-7PubMedView Article
- Gillet Y, Vanhems P, Lina G, Bes M, Vandenesch F, Floret D, Etienne J: Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis 2007, 45: 315–321. 10.1086/519263PubMedView Article
- Miles G, Movileanu L, Bayley H: Subunit composition of a bicomponent toxin: staphylococcal leukocidin forms an octameric transmembrane pore. Protein Sci 2002, 11: 894–902. 10.1110/ps.4360102PubMed CentralPubMedView Article
- Bubeck WJ, Palazzolo-Ballance AM, Otto M, Schneewind O, DeLeo FR: Panton-Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillin-resistant Staphylococcus aureus disease. J Infect Dis 2008, 198: 1166–1170. 10.1086/592053View Article
- Olsen RJ, Kobayashi SD, Ayeras AA, Ashraf M, Graves SF, Ragasa W, Humbird T, Greaver JL, Cantu C, Swain JL, Jenkins L, Blasdel T, Cagle PT, Gardner DJ, DeLeo FR, Musser JM: Lack of a major role of Staphylococcus aureus Panton-Valentine leukocidin in lower respiratory tract infection in nonhuman primates. Am J Pathol 2010, 176: 1346–1354. 10.2353/ajpath.2010.090960PubMed CentralPubMedView Article
- Hidron AI, Low CE, Honig EG, Blumberg HM: Emergence of community-acquired meticillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia. Lancet Infect Dis 2009, 9: 384–392. 10.1016/S1473-3099(09)70133-1PubMedView Article
- Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, Talan DA: Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006, 355: 666–674. 10.1056/NEJMoa055356PubMedView Article
- Health Protection Agency: PLV-Staphylococcus aureus infections: an update. Health protection report 2011., 5: News Archives
- Rasigade JP, Laurent F, Lina G, Meugnier H, Bes M, Vandenesch F, Etienne J, Tristan A: Global distribution and evolution of Panton-Valentine leukocidin-positive methicillin-susceptible Staphylococcus aureus, 1981–2007. J Infect Dis 2010, 201: 1589–1597. 10.1086/652008PubMedView Article
- Vardakas KZ, Matthaiou DK, Falagas ME: Comparison of community-acquired pneumonia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus producing the Panton-Valentine leukocidin. Int J Tuberc Lung Dis 2009, 13: 1476–1485.PubMed
- Li HT, Zhang TT, Huang J, Zhou YQ, Zhu JX, Wu BQ: Factors associated with the outcome of life-threatening necrotizing pneumonia due to community-acquired Staphylococcus aureus in adult and adolescent patients. Respiration 2011, 81: 448–460. 10.1159/000319557PubMedView Article
- Alonso-Tarres C, Villegas ML, de Gispert FJ, Cortes-Lletget MC, Rovira PA, Etienne J: Favorable outcome of pneumonia due to Panton-Valentine leukocidin-producing Staphylococcus aureus associated with hematogenous origin and absence of flu-like illness. Eur J Clin Microbiol Infect Dis 2005, 24: 756–759. 10.1007/s10096-005-0029-3PubMedView Article
- Barcelo M, Chauvet E, Boukhari R, Mbieleu B: [Staphylococcic necrotizing pneumopathy due to Panton-Valentine leukocidin toxin with good outcome]. Arch Pediatr 2009, 16: 32–36. 10.1016/j.arcped.2008.10.009PubMedView Article
- Beilouny B, Ciupea A, Eloy C, Simon G: Fatal community-acquired pneumonia due to Staphylococcus aureus carrying Panton-Valentine leukocidin genes after a stay in Africa. Intensive Care Med 2008, 34: 388–389. 10.1007/s00134-007-0854-1PubMedView Article
- Boussaud V, Parrot A, Mayaud C, Wislez M, Antoine M, Picard C, Delisle F, Etienne J, Cadranel J: Life-threatening hemoptysis in adults with community-acquired pneumonia due to Panton-Valentine leukocidin-secreting Staphylococcus aureus. Intensive Care Med 2003, 29: 1840–1843. 10.1007/s00134-003-1918-5PubMedView Article
- Chetchotisakd P, Anunnatsiri S, Puapermpoonsiri S, Prariyachatgul C, Chumpol J: A rapidly fatal case of Panton-valentine leukocidin positive Staphylococcus aureus necrotizing pneumonia in an HIV-infected patient. Southeast Asian J Trop Med Public Health 2007, 38: 690–694.PubMed
- Elizur A, Orscheln RC, Ferkol TW, Dunne WM Jr, Storch GA, Cannon CL: Transmission of Panton-Valentine leukocidin-positive Staphylococcus aureus between patients with cystic fibrosis. J Pediatr 2007, 151: 90–92. 10.1016/j.jpeds.2007.04.016PubMedView Article
- Honapour N, Mao JT: A case of fatal community-acquired necrotizing pneumonia caused by Panton-Valentine leukocidin positive methicillin-sensitive Staphylococcus aureus . Curr Respir Med Rev 2007, 3: 49–51.View Article
- Hörnig-Franz I, Kahl C, Tebbe W, Kersting C, Bürger H, Nolte K, Becker K, Bulla M, Debus O, Rabe H, Harms E: Nekrotisierende Pneumonie mit Staphylococcus aureus (pvl-Gen positiv). Monatsschrift Kinderheilkunde 2007,155(S01):S10-S15. 10.1007/s00112-005-1105-6View Article
- Hsu LY, Koh TH, Anantham D, Kurup A, Chan KP, Tan BH: Panton-Valentine leukocidin-positive Staphylococcus aureus, Singapore. Emerg Infect Dis 2004, 10: 1509–1510.PubMed CentralPubMedView Article
- Hyvernat H, Pulcini C, Carles D, Roques A, Lucas P, Hofman V, Bernardin G: Fatal Staphylococcus aureus haemorrhagic pneumonia producing Panton-Valentine leucocidin. Scand J Infect Dis 2007, 39: 183–185. 10.1080/00365540600818003PubMedView Article
- Klein JL, Petrovic Z, Treacher D, Edgeworth J: Severe community-acquired pneumonia caused by Panton-Valentine leukocidin-positive Staphylococcus aureus: first reported case in the United Kingdom. Intensive Care Med 2003, 29: 1399. 10.1007/s00134-003-1844-6PubMedView Article
- Laifer G, Frei R, Adler H, Fluckiger U: Necrotising pneumonia complicating a nasal furuncle. Lancet 2006, 367: 1628. 10.1016/S0140-6736(06)68702-3PubMedView Article
- Laporte-Turpin E, Marcoux MO, Claudet I, Grouteau E, Micheau P, Federici S, Alberge C, Prère MF: [Necrotizing pneumonia and arthritis due to Staphylococcus aureus producing Panton and Valentine leukocidin in a 10-year-old boy]. Arch Pediatr 2006, 13: 449–452. 10.1016/j.arcped.2006.02.013PubMedView Article
- Le T, Mariani-Kurkdjian P, Collignon A, Gravet A, Clermont O, Brahimi N, Gaudelus J, Aujard Y, Navarro J, Beaufils F, Bingen E: Breast milk transmission of a Panton-Valentine leukocidin-producing Staphylococcus aureus strain causing infantile pneumonia. J Clin Microbiol 2001, 39: 728–729. 10.1128/JCM.39.2.728-729.2001View Article
- Libert N, Borne M, Janvier F, Batjom E, Cirodde A, Nizou JY, Bringuin L: [Successful treatment of life-threatening Panton-Valentine leucocidin positive Staphylococcus aureus pneumonia with antibiotics and immunoglobulins targeting the toxin production]. Rev Med Interne 2009, 30: 907–910. 10.1016/j.revmed.2008.11.014PubMedView Article
- Low TB, Harty L, Murray M, Andrews C, O'Neill SJ: Panton Valentine leukocidin MSSA leading to multi-organ failure. Ir Med J 2009, 102: 185.PubMed
- Miyashita T, Shimamoto Y, Nishiya H, Koshibu Y, Sugiyama H, Ono Y, Satoh T, Haraoka H, Nakano J, Ohta K: Destructive pulmonary embolism in a patient with community-acquired staphylococcal bacteremia. J Infect Chemother 2002, 8: 99–102.PubMedView Article
- Mongkolrattanothai K, Boyle S, Kahana MD, Daum RS: Severe Staphylococcus aureus infections caused by clonally related community-acquired methicillin-susceptible and methicillin-resistant isolates. Clin Infect Dis 2003, 37: 1050–1058. 10.1086/378277PubMedView Article
- Mushtaq F, Hildrew S, Okugbeni G, Ellis RW, Deshpande S: Necrotizing haemorrhagic pneumonia proves fatal in an immunocompetent child due to Panton-Valentine Leucocidin, toxic shock syndrome toxins 1 and 2 and enterotoxin C-producing Staphylococcus aureus. Acta Paediatr 2008, 97: 985–987. 10.1111/j.1651-2227.2008.00797.xPubMedView Article
- Roberts JC, Gulino SP, Peak KK, Luna VA, Sanderson R: Fatal necrotizing pneumonia due to a Panton-Valentine leukocidin positive community-associated methicillin-sensitive Staphylococcus aureus and Influenza co-infection: a case report. Ann Clin Microbiol Antimicrob 2008,19;7(5):5.View Article
- Rouzic N, Janvier F, Libert N, Javouhey E, Lina G, Nizou JY, Pasquier P, Stamm D, Brinquin L, Pelletier C, Vandenesch F, Floret D, Etienne J, Gillet Y: Prompt and successful toxin-targeting treatment of three patients with necrotizing pneumonia due to Staphylococcus aureus strains carrying the Panton-Valentine leukocidin genes. J Clin Microbiol 2010, 48: 1952–1955. 10.1128/JCM.01892-09PubMed CentralPubMedView Article
- Salliot C, Zeller V, Puechal X, Manceron V, Sire S, Varache N, Etienne J, Desplaces N, Ziza JM: Panton-Valentine leukocidin-producing Staphylococcus aureus infections: report of 4 French cases. Scand J Infect Dis 2006, 38: 192–195. 10.1080/00365540500388776PubMedView Article
- Schefold JC, Esposito F, Storm C, Heuck D, Kruger A, Jorres A, Witte W, Hasper D: Therapy-refractory Panton Valentine Leukocidin-positive community-acquired methicillin-sensitive Staphylococcus aureus sepsis with progressive metastatic soft tissue infection: a case report. J Med Case Rep 2007, 1: 165. 10.1186/1752-1947-1-165PubMed CentralPubMedView Article
- Swaminathan A, Massasso D, Gotis-Graham I, Gosbell I: Fulminant methicillin-sensitive Staphylococcus aureus infection in a healthy adolescent, highlighting 'Panton-Valentine leucocidin syndrome'. Intern Med J 2006, 36: 744–747. 10.1111/j.1445-5994.2006.01220.xPubMedView Article
- Wenzel JJ, Hentschel J, Silvis W, Permanetter W, Mattes J, Kochanowski B et Heterich R, Jilg W, Linde HJ: Rapidly fatal necrotizing pneumonia in a 12-year-old boy caused by co-infection with parainfluenza virus type 1 and Panton-Valentine leukocidin (PVL)-positive methicillin-sensitive Staphylococcus aureus. Infection 2009, 37: 75–77. 10.1007/s15010-008-8214-9PubMedView Article
- Ebell MH, Afonso A: A systematic review of clinical decision rules for the diagnosis of influenza. Ann Fam Med 2011, 9: 69–77. 10.1370/afm.1192PubMed CentralPubMedView Article
- Lee MH, Arrecubieta C, Martin FJ, Prince A, Borczuk AC, Lowy FD: A postinfluenza model of Staphylococcus aureus pneumonia. J Infect Dis 2010, 201: 508–515. 10.1086/650204PubMed CentralPubMedView Article
- Shornick LP, Wells AG, Zhang Y, Patel AC, Huang G, Takami K, Sosa M, Shukla NA, Agapov E, Holtzman MJ: Airway epithelial versus immune cell Stat1 function for innate defense against respiratory viral infection. J Immunol 2008, 180: 3319–3328.PubMedView Article
- Mertz D, Frei R, Periat N, Zimmerli M, Battegay M, Widmer AF: Exclusive Staphylococcus aureus throat carriage: at-risk populations. Arch Intern Med 2009, 169: 172–178. 10.1001/archinternmed.2008.536PubMedView Article
- Rasigade JP, Sicot N, Laurent F, Lina G, Vandenesch F, Etienne J: A history of Panton-Valentine leukocidin (PVL)-associated infection protects against death in PVL-associated pneumonia. Vaccine 2011, 29: 4185–4186. 10.1016/j.vaccine.2011.04.033PubMedView Article
- Acton DS, Plat-Sinnige MJ, van Wamel W, de Groot N, van Belkum A: Intestinal carriage of Staphylococcus aureus: how does its frequency compare with that of nasal carriage and what is its clinical impact? Eur J Clin Microbiol Infect Dis 2009, 28: 115–127. 10.1007/s10096-008-0602-7PubMedView Article
- von Eiff C, Becker K, Machka K, Stammer H, Peters G: Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med 2001, 344: 11–16. 10.1056/NEJM200101043440102PubMedView Article
- Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, Nouwen JL: The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 2005, 5: 751–762. 10.1016/S1473-3099(05)70295-4PubMedView Article
- Noel C, Florquin S, Goldman M, Braun MY: Chronic exposure to superantigen induces regulatory CD4(+) T cells with IL-10-mediated suppressive activity. Int Immunol 2001, 13: 431–439. 10.1093/intimm/13.4.431PubMedView Article
- Brown EL, Dumitrescu O, Thomas D, Badiou C, Koers EM, Choudhury P, Vazquez V, Etienne J, Lina G, Vandenesch F, Bowden MG: The Panton-Valentine leukocidin vaccine protects mice against lung and skin infections caused by Staphylococcus aureus USA300. Clin Microbiol Infect 2009, 15: 156–164.View Article
- Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE: Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007, 195: 202–211. 10.1086/510396PubMedView Article
- Dumitrescu O, Badiou C, Bes M, Reverdy ME, Vandenesch F, Etienne J, Lina G: Effect of antibiotics, alone and in combination, on Panton-Valentine leukocidin production by a Staphylococcus aureus reference strain. Clin Microbiol Infect 2008, 14: 384–388. 10.1111/j.1469-0691.2007.01947.xPubMedView Article
- Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG: Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007,44(Suppl 2):S27-S72.PubMedView Article
- Health Protection Agency 2nd edition. 2008.
- Gillet Y, Dumitrescu O, Tristan A, Dauwalder O, Javouhey E, Floret D, Vandenesch F, Etienne J, Lina G: Pragmatic management of Panton-Valentine leukocidin-associated staphylococcal diseases. Int J Antimicrob Agents 2011, 38: 457–464. 10.1016/j.ijantimicag.2011.05.003PubMedView Article
- Adem PV, Montgomery CP, Husain AN, Koogler TK, Arangelovich V, Humilier M, Boyle-Vavra S, Daum RS: Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N Engl J Med 2005, 353: 1245–1251. 10.1056/NEJMoa044194PubMedView Article
- Gauduchon V, Cozon G, Vandenesch F, Genestier AL, Eyssade N, Peyrol S, Etienne J, Lina G: Neutralization of Staphylococcus aureus Panton Valentine leukocidin by intravenous immunoglobulin in vitro. J Infect Dis 2004, 189: 346–353. 10.1086/380909PubMedView Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.